Literature DB >> 21907121

The effects of D-penicillamine on a murine model of oxygen-induced retinopathy.

R Michael Siatkowski1, Tammy L Yanovitch, John D Ash, Annie Moreau.   

Abstract

PURPOSE: To determine the effect of intraperitoneal and intravitreal D-penicillamine (DPA) on retinal neovascularization in a murine model of oxygen-induced retinopathy.
METHODS: On postnatal day 7, 16 mice were injected intraperitoneally with 300 mg/kg/day DPA for 3 days followed by 50 mg/kg/day for 7 days. A different group of 7 mice were injected intraperitoneally with 600 mg/kg/day DPA for 3 days followed by 100 mg/kg/day for 7 days. A third group of 14 mice were injected with 1,500 mg/kg/day DPA for 2 days; a control cohort of 17 mice received intraperitoneal phosphate-buffered saline (PBS). An additional 15 mice underwent intravitreal injection of 1 μL of 100 mg/mL DPA in the right eye and 1 μL PBS intravitreally in the left eye as a control. All groups were placed in a 75% oxygen chamber for 7 days then room air for 3 days before being sacrificed and enucleated. The retinas were stained and flat-mounted to determine the severity of retinal neovascularization by quantifying neovascular buds.
RESULTS: After intraperitoneal injection, the mean number of glomeruli and tubules was similar in the DPA and PBS groups (P = 1.0), regardless of DPA dosage. The dosage of 1,500 mg/kg/day proved to be uniformly lethal. After intravitreal injections, the mean number of glomeruli (P = 0.16) and tubules (P = 0.7) were similar in the DPA and PBS groups.
CONCLUSIONS: Neither intraperitoneal nor intravitreal injection of DPA inhibits retinal neovascularization in a murine model of oxygen-induced retinopathy.
Copyright © 2011 American Association for Pediatric Ophthalmology and Strabismus. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21907121      PMCID: PMC3644968          DOI: 10.1016/j.jaapos.2011.04.005

Source DB:  PubMed          Journal:  J AAPOS        ISSN: 1091-8531            Impact factor:   1.220


  15 in total

Review 1.  D-Penicillamine for preventing retinopathy of prematurity in preterm infants.

Authors:  D L Phelps; L Lakatos; J L Watts
Journal:  Cochrane Database Syst Rev       Date:  2001

2.  D-penicillamine therapy of neonatal hyperbilirubinaemia.

Authors:  L Lakatos; B Kövér; F Péter
Journal:  Acta Paediatr Acad Sci Hung       Date:  1974

3.  Oxygen-induced retinopathy in the rat: possible contribution of peroxidation reactions.

Authors:  J S Penn
Journal:  Doc Ophthalmol       Date:  1990-03       Impact factor: 2.379

Review 4.  Autoxidative damage to the retina: potential role in retinopathy of prematurity.

Authors:  M L Katz; W G Robison
Journal:  Birth Defects Orig Artic Ser       Date:  1988

5.  D-Penicillamine administration and the incidence of retinopathy of prematurity.

Authors:  R D Christensen; S C Alder; S C Richards; D K Lambert; N Schmutz; S E Wiedmeier; J Burnett; V L Baer; J T Horn; M Richards; J Barraza
Journal:  J Perinatol       Date:  2007-02       Impact factor: 2.521

6.  One year longitudinal follow-up of premature infants treated with D-penicillamine in the neonatal period.

Authors:  S Vekerdy-Lakatos; L Lakatos; G Oroszlán; B Itzés
Journal:  Acta Paediatr Hung       Date:  1987

7.  Controlled trial of D-penicillamine to prevent retinopathy of prematurity.

Authors:  L Lakatos; I Hatvani; G Oroszlán; G Balla; L Karmazsin; O Alaka; E Kincses; I Szabó; Z Lakatos
Journal:  Acta Paediatr Hung       Date:  1986

Review 8.  Pathogenesis of retinopathy of prematurity.

Authors:  Lois E H Smith
Journal:  Growth Horm IGF Res       Date:  2004-06       Impact factor: 2.372

9.  D-penicillamine treatment of hyperbilirubinaemia in preterm infants.

Authors:  G Korányi; J Kovács; I Vörös
Journal:  Acta Paediatr Acad Sci Hung       Date:  1978

10.  Vitamin E in kitten oxygen-induced retinopathy. II. Blockage of vitreal neovascularization.

Authors:  D L Phelps; A L Rosenbaum
Journal:  Arch Ophthalmol       Date:  1979-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.